OARSI 2023 SYMPOSIUM
FROM BIOMARKERS TO PRECISION MEDICINE IN KNEE OSTEOARTHRITIS

JUNE 22-23
A Coruña
Spain
SCIENTIFIC COMMITTEE

Francisco J Blanco
Francisco Castro
Gun-il Im
Cristobal Orellana
Cristina Ruiz-Romero
THURSDAY, JUNE 22nd

13.50-14.00 h  WELCOME

PART I: BIOMARKERS IN OA

14.00-15.00 h  SESSION 1: Molecular biomarkers for the identification of endotypes in OA
   14.00-14.20 h  Genetics, Genomics and Epigenetics  To be confirmed
   14.20-14.40 h  Proteomics, Metabolomics and Lipidomics  Ali Mobasheri
   14.40-15.00 h  Discussion and conclusions

15.00-16.20 h  SESSION 2: Molecular biomarkers for the diagnosis and prognosis of OA phenotypes
   15.00-15.20 h  Genetics, Genomics and Epigenetics  Sarah Rice
   15.20-15.40 h  Mitochondrial genetics  Alejandro Durán
   15.40-16.00 h  Proteomics, Metabolomics and Lipidomics  To be confirmed
   16.00-16.20 h  Discussion and conclusions

16.20-17.00 h  COFFEE BREAK & POSTERS

17.00-19.00 h  SESSION 3: Clinical and imaging biomarkers
   17.00-17.20 h  OA Phenotypes defined by clinical biomarkers  Margreet Kloppenburg
   17.20-17.40 h  Regression to the mean and its importance for pain outcomes in OA clinical trials  Martin Englund
   17.40-18.00 h  Structural Fast Progression  Wolfgang Wirth
   18.00-18.20 h  The Knee Osteoarthritis Prediction (KNOAP2020) challenge  Jukka Hirvasniemi
   18.20-19.00 h  Discussion and conclusions

20.00 h  GALA DINNER

FRIDAY, JUNE 23rd

PART II: THERAPY IN OA

09.00-09.50 h  SESSION 4: Presentation of Oral Abstracts
   09.00-09.10 h  Abstract 1
   09.10-09.20 h  Abstract 2
   09.20-09.30 h  Abstract 3
   09.30-09.40 h  Abstract 4
   09.40-09.50 h  Abstract 5

09.50-10.20 h  COFFEE BREAK AND POSTERS

10.20-12.30 h  SESSION 5: Therapy in OA
   10.20-10.40 h  Senolytics, Senescence, Aging  Martin Lotz
   10.40-11.00 h  Regenerative Therapies/Chondrogenesis Inductors  Gun-il Im
   11.00-11.20 h  Inflamming and Nutritional treatments  Yves Henrotin
   11.20-11.40 h  Metabolic Therapy  David Hunter
   11.40-12.00 h  New pharmacological therapies for pain and structure modification  Phil Conaghan
   12.00-12.30 h  Discussion and conclusions

12.30-14.00 h  LUNCH AND POSTERS

PART III: PRECISION MEDICINE IN OA

14.00-15.20 h  SESSION 6: Pain in OA
   14.00-14.20 h  Identification of novel targets for osteoarthritis pain  Rachel E Miller
   14.20-14.40 h  Osteoarthritis chronic pain phenotype  Mylene P Jansen
   14.40-15.00 h  Associations between biomarkers of matrix metabolism and inflammation with pain and fatigue  To be confirmed
   15.00-15.20 h  Discussion and conclusions
15.20-16.20 h SESSION 7: Patients and RRI
15.20-15.40 h Point of view of the Dutch Arthritis Foundation
Corné Baatenburg de Jong
15.40-16.00 h Point of view of OAFI
Josep Vergés
16.00-16.20 h Discussion and conclusions

16.20-17.00 h COFFEE BREAK AND POSTERS

17.00-18.00 h SESSION 8: Precision Medicine in Pre-Radiographic OA
17.00-17.20 h Definition of Early OA
Fiona Watt
17.20-17.40 h Definition of Asymptomatic OA phase (Prevention OA)
Sebastián de la Cruz Rodríguez
17.40-18.00 h Discussion and conclusions

18.00-19.00 h SESSION 9: Debate: Is OA ready for precision medicine?
18.00-18.20 h OA is ready to apply for precision medicine
Rik Lories
18.20-18.40 h It is not time yet for precision medicine in OA
Simon Mastbergen
18.40-19.00 h Discussion and conclusions

19.00h CLOSING

SPEAKERS

Corné Baatenburg de Jong
Deputy Director and Manager of Operations and Funding. Dutch Arthritis Society, the Netherlands

Josep Vergés
President and CEO of the Osteoarthritis Foundation International, Spain

Margreet Kloppenburg
Department of Rheumatology, Leiden University Medical Center, the Netherlands

Rik Lories
Department of Development and Regeneration, KU Leuven, Belgium

Phil Conaghan
Department of Rheumatology, Leeds Teaching Hospitals Trust, United Kingdom

Sebastián de la Cruz
Medical Affairs, ICON, Spain

Phil Conaghan
Department of Rheumatology, Leeds Teaching Hospitals Trust, United Kingdom

Sebastián de la Cruz
Medical Affairs, ICON, Spain

Alejandro Durán
Department of Rheumatology Investigation, Instituto de Investigación Biomédica de A Coruña, Spain

Martin Englund
Clinical Epidemiology Unit, Lund University, Sweden

Jukka Hirvasniemi
Department of Radiology, Erasmus MC, the Netherlands

David Hunter
Sydney Musculoskeletal Health Flagship, University of Sydney, Australia

Gun-il Im
Department of Orthopaedics, Dongguk University, South Korea

Mylène P Jansen
Department of Rheumatology, University Medical Center Utrecht, the Netherlands

Margreet Kloppenburg
Department of Rheumatology, Leiden University Medical Center, the Netherlands

Rik Lories
Department of Development and Regeneration, KU Leuven, Belgium

Phil Conaghan
Department of Rheumatology, Leeds Teaching Hospitals Trust, United Kingdom

Sebastián de la Cruz
Medical Affairs, ICON, Spain

Alejandro Durán
Department of Rheumatology Investigation, Instituto de Investigación Biomédica de A Coruña, Spain

Martin Englund
Clinical Epidemiology Unit, Lund University, Sweden

Jukka Hirvasniemi
Department of Radiology, Erasmus MC, the Netherlands

David Hunter
Sydney Musculoskeletal Health Flagship, University of Sydney, Australia

Gun-il Im
Department of Orthopaedics, Dongguk University, South Korea

Mylène P Jansen
Department of Rheumatology, University Medical Center Utrecht, the Netherlands

Margreet Kloppenburg
Department of Rheumatology, Leiden University Medical Center, the Netherlands

Rik Lories
Department of Development and Regeneration, KU Leuven, Belgium

Phil Conaghan
Department of Rheumatology, Leeds Teaching Hospitals Trust, United Kingdom

Sebastián de la Cruz
Medical Affairs, ICON, Spain

Alejandro Durán
Department of Rheumatology Investigation, Instituto de Investigación Biomédica de A Coruña, Spain

Martin Englund
Clinical Epidemiology Unit, Lund University, Sweden

Jukka Hirvasniemi
Department of Radiology, Erasmus MC, the Netherlands

David Hunter
Sydney Musculoskeletal Health Flagship, University of Sydney, Australia

Gun-il Im
Department of Orthopaedics, Dongguk University, South Korea

Mylène P Jansen
Department of Rheumatology, University Medical Center Utrecht, the Netherlands

Margreet Kloppenburg
Department of Rheumatology, Leiden University Medical Center, the Netherlands

Rik Lories
Department of Development and Regeneration, KU Leuven, Belgium

Phil Conaghan
Department of Rheumatology, Leeds Teaching Hospitals Trust, United Kingdom

Sebastián de la Cruz
Medical Affairs, ICON, Spain

Alejandro Durán
Department of Rheumatology Investigation, Instituto de Investigación Biomédica de A Coruña, Spain

Martin Englund
Clinical Epidemiology Unit, Lund University, Sweden

Jukka Hirvasniemi
Department of Radiology, Erasmus MC, the Netherlands

David Hunter
Sydney Musculoskeletal Health Flagship, University of Sydney, Australia

Gun-il Im
Department of Orthopaedics, Dongguk University, South Korea

Mylène P Jansen
Department of Rheumatology, University Medical Center Utrecht, the Netherlands

Margreet Kloppenburg
Department of Rheumatology, Leiden University Medical Center, the Netherlands

Rik Lories
Department of Development and Regeneration, KU Leuven, Belgium

Phil Conaghan
Department of Rheumatology, Leeds Teaching Hospitals Trust, United Kingdom

Sebastián de la Cruz
Medical Affairs, ICON, Spain

Alejandro Durán
Department of Rheumatology Investigation, Instituto de Investigación Biomédica de A Coruña, Spain

Martin Englund
Clinical Epidemiology Unit, Lund University, Sweden

Jukka Hirvasniemi
Department of Radiology, Erasmus MC, the Netherlands

David Hunter
Sydney Musculoskeletal Health Flagship, University of Sydney, Australia

Gun-il Im
Department of Orthopaedics, Dongguk University, South Korea

Mylène P Jansen
Department of Rheumatology, University Medical Center Utrecht, the Netherlands

Margreet Kloppenburg
Department of Rheumatology, Leiden University Medical Center, the Netherlands

Rik Lories
Department of Development and Regeneration, KU Leuven, Belgium

Phil Conaghan
Department of Rheumatology, Leeds Teaching Hospitals Trust, United Kingdom

Sebastián de la Cruz
Medical Affairs, ICON, Spain

Alejandro Durán
Department of Rheumatology Investigation, Instituto de Investigación Biomédica de A Coruña, Spain

Martin Englund
Clinical Epidemiology Unit, Lund University, Sweden

Jukka Hirvasniemi
Department of Radiology, Erasmus MC, the Netherlands

David Hunter
Sydney Musculoskeletal Health Flagship, University of Sydney, Australia

Gun-il Im
Department of Orthopaedics, Dongguk University, South Korea

Mylène P Jansen
Department of Rheumatology, University Medical Center Utrecht, the Netherlands

Margreet Kloppenburg
Department of Rheumatology, Leiden University Medical Center, the Netherlands

Rik Lories
Department of Development and Regeneration, KU Leuven, Belgium

Phil Conaghan
Department of Rheumatology, Leeds Teaching Hospitals Trust, United Kingdom

Sebastián de la Cruz
Medical Affairs, ICON, Spain

Alejandro Durán
Department of Rheumatology Investigation, Instituto de Investigación Biomédica de A Coruña, Spain

Martin Englund
Clinical Epidemiology Unit, Lund University, Sweden

Jukka Hirvasniemi
Department of Radiology, Erasmus MC, the Netherlands

David Hunter
Sydney Musculoskeletal Health Flagship, University of Sydney, Australia

Gun-il Im
Department of Orthopaedics, Dongguk University, South Korea

Mylène P Jansen
Department of Rheumatology, University Medical Center Utrecht, the Netherlands

Margreet Kloppenburg
Department of Rheumatology, Leiden University Medical Center, the Netherlands

Rik Lories
Department of Development and Regeneration, KU Leuven, Belgium

Phil Conaghan
Department of Rheumatology, Leeds Teaching Hospitals Trust, United Kingdom

Sebastián de la Cruz
Medical Affairs, ICON, Spain

Alejandro Durán
Department of Rheumatology Investigation, Instituto de Investigación Biomédica de A Coruña, Spain

Martin Englund
Clinical Epidemiology Unit, Lund University, Sweden

Jukka Hirvasniemi
Department of Radiology, Erasmus MC, the Netherlands

David Hunter
Sydney Musculoskeletal Health Flagship, University of Sydney, Australia

Gun-il Im
Department of Orthopaedics, Dongguk University, South Korea

Mylène P Jansen
Department of Rheumatology, University Medical Center Utrecht, the Netherlands

Margreet Kloppenburg
Department of Rheumatology, Leiden University Medical Center, the Netherlands

Rik Lories
Department of Development and Regeneration, KU Leuven, Belgium

Phil Conaghan
Department of Rheumatology, Leeds Teaching Hospitals Trust, United Kingdom

Sebastián de la Cruz
Medical Affairs, ICON, Spain

Alejandro Durán
Department of Rheumatology Investigation, Instituto de Investigación Biomédica de A Coruña, Spain

Martin Englund
Clinical Epidemiology Unit, Lund University, Sweden

Jukka Hirvasniemi
Department of Radiology, Erasmus MC, the Netherlands

David Hunter
Sydney Musculoskeletal Health Flagship, University of Sydney, Australia

Gun-il Im
Department of Orthopaedics, Dongguk University, South Korea

Mylène P Jansen
Department of Rheumatology, University Medical Center Utrecht, the Netherlands

Margreet Kloppenburg
Department of Rheumatology, Leiden University Medical Center, the Netherlands

Rik Lories
Department of Development and Regeneration, KU Leuven, Belgium

Phil Conaghan
Department of Rheumatology, Leeds Teaching Hospitals Trust, United Kingdom

Sebastián de la Cruz
Medical Affairs, ICON, Spain

Alejandro Durán
Department of Rheumatology Investigation, Instituto de Investigación Biomédica de A Coruña, Spain

Martin Englund
Clinical Epidemiology Unit, Lund University, Sweden

Jukka Hirvasniemi
Department of Radiology, Erasmus MC, the Netherlands

David Hunter
Sydney Musculoskeletal Health Flagship, University of Sydney, Australia

Gun-il Im
Department of Orthopaedics, Dongguk University, South Korea

Mylène P Jansen
Department of Rheumatology, University Medical Center Utrecht, the Netherlands
ABSTRACTS

KEY INFORMATION
- Your work must be submitted via email at symposiumoarsi@ser.es before 21 May.
- This submission must include your work attached, and the following fields:
  - Abstract title
  - Authors
  - Hospital/Institution
  - Body (up to 3,500 characters)
  - Corresponding author
  - Corresponding e-mail
- A confirmation e-mail will be sent to your e-mail address.
- 5 projects will be selected as oral communications to be presented in SESSION 4 of the Scientific Programme. The remaining abstracts will be presented as posters in the exhibition area.
- The final evaluation will be communicated to the corresponding author after 29 May.

ABSTRACT FORMAT
- In the body of the abstract, the character limit is set at 3,500 characters, including text spaces (tables/images are excluded from this character limit).
- Optionally, you may include a maximum of three images (*.jpg and *.png formats) with a maximum file size of 5MB and a resolution of at least 300 dpi. It will be necessary to include a “reference” in the body text of the abstract that refers to the image/graphic. E.g. (image 1, graphic 1, etc.).

Please note that the deadline for submission is 21 May 2023, at 23.59h (UTC+2).
For any assistance regarding your submission, please contact symposiumoarsi@ser.es
REGISTRATION

<table>
<thead>
<tr>
<th>CATEGORIES</th>
<th>REG</th>
<th>ON-SITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MD, Professor, PhD, lab director</td>
<td>200€</td>
<td>250€</td>
</tr>
<tr>
<td>Postdoc, Student, Resident, Fellow, Nurse, etc</td>
<td>100€</td>
<td>150€</td>
</tr>
</tbody>
</table>

* Please note that registration fees do not include travel expenses, accommodation and the Gala Dinner.

To access the program and complete your registration, please visit the website: [www.ser.es/inscripciones/](http://www.ser.es/inscripciones/) and complete the Symposium form.

To attend the Gala Dinner on 22 June, registration on the cited website is required.

For any information related to registration and accommodation of this Symposium please send an email to: uniontours@uniontours.es or contact by phone at +34 93 419 20 30.

TECHNICAL SECRETARY

FUNDACIÓN ESPAÑOLA DE REUMATOLOGÍA
C/ Marqués del Duero, 5 - 1ª 28001 Madrid
Tel: 91 576 77 99 ser@ser.es www.ser.es